GoAI
Get started
Upstream Bio, Inc. logo

Upstream Bio, Inc.

UPB

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$6.97

+$0.12 · +1.75%

Aug 21, 4:00 PM ET

UPB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

51

Fair Value

Momentum

27

Weakening

Sentiment

42

Mixed

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
E. Rand Sutherland
Listed since
Oct 11, 2024
Employees
75

Market position

Day range

Current $6.97

52-week range

Current $6.97

Open
$6.98
Previous close
$6.85
Volume
434.24K
0.73× average
Average volume
591.33K
Average daily volume
Market cap
379.31M USD
Beta
1.27
Market reference 1
50-day average
$6.8479
+1.78% above average
200-day average
$14.765
-52.79% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.36B USD
P/E (TTM)
-2.4×
P/B (TTM)
1.4×
P/S (TTM)
120.11×
EV / EBITDA
-9.51×
Earnings yield
-9.81%
Free cash flow yield
-9.12%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
98.45%
Operating margin
-5382.65%
Net margin
-4955.67%
Return on equity
-42.22%
Return on assets
-40.55%
Return on invested capital
-47.02%

Financial health

Debt / equity
0×
Current ratio
26.15×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends672%-1616%-3903%-6191%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2022: -1972.69%Operating margin, FY2023: -1685.46%Operating margin, FY2024: -3281.18%Operating margin, FY2025: -5618.82%Net margin, FY2022: -1969.31%Net margin, FY2023: -862.90%Net margin, FY2024: -2650.04%Net margin, FY2025: -5026.03%FY2022FY2023FY2024FY2025
Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2022 -1972.69%. Operating margin FY2023 -1685.46%. Operating margin FY2024 -3281.18%. Operating margin FY2025 -5618.82%. Net margin FY2022 -1969.31%. Net margin FY2023 -862.90%. Net margin FY2024 -2650.04%. Net margin FY2025 -5026.03%.

Income trends

Revenue

2.85M USD+20.42%

Operating income

−160.36M USD-106.21%

Net income

−143.44M USD-128.39%
Income trends across reported periods19.18M USD−46.11M USD−111.4M USD−176.68M USDRevenue, FY2022: 1.21M USDRevenue, FY2023: 2.38M USDRevenue, FY2024: 2.37M USDRevenue, FY2025: 2.85M USDOperating income, FY2022: −23.91M USDOperating income, FY2023: −40.11M USDOperating income, FY2024: −77.76M USDOperating income, FY2025: −160.36M USDNet income, FY2022: −23.87M USDNet income, FY2023: −20.54M USDNet income, FY2024: −62.81M USDNet income, FY2025: −143.44M USDFY2022FY2023FY2024FY2025
Revenue FY2022 1.21M USD. Revenue FY2023 2.38M USD. Revenue FY2024 2.37M USD. Revenue FY2025 2.85M USD. Operating income FY2022 −23.91M USD. Operating income FY2023 −40.11M USD. Operating income FY2024 −77.76M USD. Operating income FY2025 −160.36M USD. Net income FY2022 −23.87M USD. Net income FY2023 −20.54M USD. Net income FY2024 −62.81M USD. Net income FY2025 −143.44M USD.
Metric (USD)FY2025FY2024FY2023FY2022
Revenue2.85M USD2.37M USD2.38M USD1.21M USD
Gross profit2.85M USD2.37M USD2.38M USD1.21M USD
Research and development136.81M USD62.97M USD31.8M USD18.66M USD
Selling, general, and administrative26.41M USD17.17M USD10.7M USD6.46M USD
Operating expenses163.22M USD80.13M USD42.49M USD25.12M USD
Interest income16.93M USD12.12M USD4.17M USD205K USD
Depreciation and amortization188K USD89K USD60K USD7K USD
Operating income−160.36M USD−77.76M USD−40.11M USD−23.91M USD
Net income−143.44M USD−62.81M USD−20.54M USD−23.87M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
25%
2 beats, 5 misses, 1 met estimate
Average EPS surprise
-148.56%
8 comparable reports
Latest EPS result
-0.73
Estimate -0.73 · Miss by 0.61%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.37-0.52-0.68-0.83Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MetQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual -0.41, estimate -0.56, surprise +26.79%, Beat. Q2 2025, reported May 6, 2025: actual -0.51, estimate -0.49, surprise -4.08%, Miss. Q3 2025, reported Aug 6, 2025: actual -0.74, estimate -0.61, surprise -21.31%, Miss. Q4 2025, reported Nov 5, 2025: actual -0.63, estimate -0.78, surprise +19.23%, Beat. Q1 2026, reported Mar 26, 2026: actual -0.79, estimate -0.73, surprise -8.22%, Miss. Q2 2026, reported May 13, 2026: actual -0.75, estimate -0.75, surprise 0.00%, Met estimate. Q3 2026, reported Aug 11, 2026: actual -0.73, estimate -0.726, surprise -0.61%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.731, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.09M817.39K543.42K269.45KQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual 613K USD, estimate 384.78K USD, surprise +59.31%, Beat. Q2 2025, reported May 6, 2025: actual 566K USD, estimate 317K USD, surprise +78.55%, Beat. Q3 2025, reported Aug 6, 2025: actual 937K USD, estimate 317K USD, surprise +195.58%, Beat. Q4 2025, reported Nov 5, 2025: actual 683K USD, estimate 521.57K USD, surprise +30.95%, Beat. Q1 2026, reported Mar 26, 2026: actual 668K USD, estimate 584K USD, surprise +14.38%, Beat. Q2 2026, reported May 13, 2026: actual 1.03M USD, estimate 1.03M USD, surprise +0.62%, Beat. Q3 2026, reported Aug 11, 2026: actual 773K USD, estimate 561.38K USD, surprise +37.70%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 522.5K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy250%
Hold250%
Sell00%
Strong sell00%

UPB news

gurufocus.com

Fannie Mae Announces Sale of Non-Performing Loans

Fannie Mae Announces Sale of Non-Performing Loans PR Newswire WASHINGTON, Aug. 19, 2026

Read source
zacks.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.

Read source
zacks.com

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read source
gurufocus.com

Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction

Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction PR Newswire WASHINGTON,

Read source
globenewswire.com

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Read source
businesswire.com

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 65 classes of mortgage pass-through notes from OBX 2026-AHC2 Trust, a prime agency-eligible RMBS transaction sponsored by Onslow Bay…

Read source

UPB peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding UPB

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
9.11M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
6.21M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.53M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.3M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
1.85M
Weight
0.02%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.25M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.1M
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
1.03M
Weight
0.01%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%

Continue in GoAI

Research UPB

research.disclaimer